Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infigratinib in Children With Hypochondroplasia (ACCEL 2/3)
NCT06873035Phase 3Enrolling by invitation
- Sponsor
- QED Therapeutics
- Start
- Apr 2025
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 3, randomised, double-blind trial of infigratinib in hypochondroplasia (HCH) (2 cohorts), sponsored by QED Therapeutics. Primary endpoints: Annualized Height Velocity at 26 weeks and Adverse Events at 26 weeks. Started Apr 2025; status: enrolling by invitation.
02
Drugs
infigratinib
03
Conditions
hypochondroplasia (HCH)
Beyond the preview
Go deeper on NCT06873035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06873035.